SAMD4B and breast carcinoma: These results preliminarily demonstrate that SAMD4B enhances the transcriptional activity of TCF/LEF, the key downstream effector of the Wnt/β-catenin pathway, suggesting that SAMD4B activates this pathway in breast cancer cells.